Efficacy and Safety of HGXJT in Bone Metastatic NSCLC Patients

This is a double-blind, randomized controlled study evaluating the efficacy and safety of HGXJT in combination with ICI-based standard treatment in lung cancer patients with bone metastases. Enrolled participates will randomly receive HGXJT or placebo during the first 4-6 cycles of ICI-based standard treatment.

Trial Details

NCT ID
NCT05378334
Phase
NA
Sponsor
Guangzhou University of Traditional Chinese Medicine
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • ICI
  • Chemotherapy
  • Placebo
  • Bone-protecting and Mass-dispersesing Decoction
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Patients with non-small cell lung cancer diagnosed by histopathology or cytopathology.
  • Presence of bone metastases.
  • EGFR/ALK gene wild type.
  • No prior treatment with PD-1 inhibitors (combination or monotherapy)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →